Search

everythinglearnresearchcommunity

for

Search:↓

The user had a hair transplant in December 2024 and started using topical minoxidil and finasteride in March 2025, along with dermarolling and multivitamins. They are experiencing increased hair shedding and are questioning if it's the "dread shed" phase.

The user is considering switching from oral to topical minoxidil and possibly adding finasteride, while continuing with dutasteride and incorporating microneedling to improve hair loss treatment. They are concerned about potential shedding during the transition.

The conversation discusses using a low dose of topical finasteride to achieve hair benefits with minimal systemic exposure. Users share experiences and opinions on dosing, systemic buildup, and side effects of both topical and oral finasteride.

Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.

The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

The conversation discusses concerns about MVSupplements.com products, specifically the Min+Ru spray and GHK Serum, due to discrepancies in ingredient lists and recent poor feedback. Users also mention a price increase and one user reports no issues with the RU powder.

A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

The conversation is about a user experiencing hair loss who has been using finasteride for a year and minoxidil once a day for five months, but still experiences shedding and thin hair. The user is considering switching to dutasteride next year and shares their progress with others using similar treatments.

User "al_ick" shares progress with topical fin, min, tret, and micro needling for hair loss, showing good results. They use hims fin and min combination spray, applying 5-7 sprays for better coverage.

A user is seeking advice on obtaining oral minoxidil in Australia through telehealth services. They are considering options like Mosh and are unsure if they should mention previous use or claim it's for hypertension.

The user is experiencing aggressive diffuse thinning despite using 1mg oral finasteride daily, topical minoxidil twice, microneedling, and Nizoral for seborrheic dermatitis. They are considering switching to dutasteride or RU58841 but are advised to seek a second opinion to determine the cause of hair loss.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

A humorous discussion about hair loss treatments, specifically mentioning the use of 5mg of Dutasteride. The conversation includes jokes about the effectiveness of the treatment.

A humorous discussion about hair loss treatments, specifically mentioning minoxidil and oral use. The conversation includes a satirical take on a worker at a minoxidil factory.

The user is considering switching from an expensive topical hair loss treatment containing 8% Minoxidil, 0.3% Finasteride, Retinoic Acid, and Hydrocortisone to a cheaper Kirkland brand Minoxidil. They are concerned about the effectiveness of the lower concentration and the absence of additional ingredients.

The user experienced negative side effects from oral minoxidil, including cardiac issues and excessive sweating, and decided to switch to topical minoxidil while using other treatments like RU58841, Setipiprant, Azelaic acid, and latanoprost. Another user suggested splitting the oral minoxidil dose to reduce side effects.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation discusses hair loss treatments, specifically the use of 5% topical minoxidil, with considerations for adding finasteride or dutasteride. Concerns about side effects, such as unwanted body hair growth from oral minoxidil, are also mentioned.

The user has been using topical minoxidil and dutasteride but is experiencing significant hair shedding, including smaller hairs. They are concerned if this shedding indicates the treatment is working.

The user has been using finasteride and minoxidil for 7 months, seeing thicker hair but no temple regrowth, and is considering switching to dutasteride. Another person suggested trying microneedling on the temples before changing medications.

The conversation discusses a user's 3.5-month experience using pyrilutamide and minoxidil for hair loss, with some perceived improvement in the temples but potential recent regression. Another user suggests that maintaining the current hairline, even without improvement, is positive.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.

The conversation discusses using topical finasteride and minoxidil for hair loss, focusing on the crown and mid-scalp areas. The user is optimistic about seeing results in 3 to 6 months.

The conversation is about someone's progress with hair loss treatment using topical finasteride, minoxidil, and weekly manual microneedling. A reply indicates that they have made noticeable progress.

The user noticed miniaturized hair at the front of their hairline and is not on any medication. They are concerned if this is a sign of a receding hairline or something normal.